Literature DB >> 23163568

Trends in transfusion burden among long-term survivors of childhood hematological malignancies.

Kerri Nottage1, James G Gurney, Matthew Smeltzer, Maria Castellanos, Melissa M Hudson, Jane S Hankins.   

Abstract

The risk from cumulative erythrocyte transfusions is poorly understood in oncology populations. This analysis among long-term survivors explored variation in transfusional burden over progressive eras of treatment identifying those at risk for iron overload. Transfusion records of 982 survivors of hematological malignancies treated at St. Jude were reviewed. After exclusions, 881 (90%) were assessed for cumulative volume, weight-adjusted volume and transfusion number. Treatment intensity was assigned using the Intensity of Treatment Rating Scale version 3.0 (ITR-3). Hematopoietic stem cell transplant and acute myeloid leukemia survivors had greater transfusional burden than conventional therapy recipients and acute lymphoblastic leukemia survivors, respectively. Survivors of 5-10 years were more likely than survivors of > 10 years to receive ≥ 10 transfusions (odds ratio = 2.0, 95% confidence interval 1.5-2.8). Those with higher ITR-3 scores and more recent decades of treatment had a higher transfusional burden. Comprehensive transfusion histories are useful in identifying those at highest risk for iron overload.

Entities:  

Mesh:

Year:  2012        PMID: 23163568      PMCID: PMC3927453          DOI: 10.3109/10428194.2012.750724

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  30 in total

1.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload.

Authors:  L J Anderson; S Holden; B Davis; E Prescott; C C Charrier; N H Bunce; D N Firmin; B Wonke; J Porter; J M Walker; D J Pennell
Journal:  Eur Heart J       Date:  2001-12       Impact factor: 29.983

2.  Association of projected transfusional iron burden with treatment intensity in childhood cancer survivors.

Authors:  Kathleen S Ruccione; Kiran Mudambi; Richard Sposto; Joy Fridey; Suzy Ghazarossian; David R Freyer
Journal:  Pediatr Blood Cancer       Date:  2011-12-20       Impact factor: 3.167

3.  Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood.

Authors:  M Taskinen; U M Saarinen-Pihkala; L Hovi; M Lipsanen-Nyman
Journal:  Lancet       Date:  2000-09-16       Impact factor: 79.321

4.  Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassaemia.

Authors:  R A Risdon; M Barry; D M Flynn
Journal:  J Pathol       Date:  1975-06       Impact factor: 7.996

5.  Survival and causes of death in thalassaemia major.

Authors:  M G Zurlo; P De Stefano; C Borgna-Pignatti; A Di Palma; A Piga; C Melevendi; F Di Gregorio; M G Burattini; S Terzoli
Journal:  Lancet       Date:  1989-07-01       Impact factor: 79.321

6.  Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood.

Authors:  Katarina Link; Christian Moëll; Stanislaw Garwicz; Eva Cavallin-Ståhl; Jonas Björk; Ulf Thilén; Bo Ahrén; Eva Marie Erfurth
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

7.  Survival in medically treated patients with homozygous beta-thalassemia.

Authors:  N F Olivieri; D G Nathan; J H MacMillan; A S Wayne; P P Liu; A McGee; M Martin; G Koren; A R Cohen
Journal:  N Engl J Med       Date:  1994-09-01       Impact factor: 91.245

8.  Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion.

Authors:  P A Merkel; D C Simonson; S A Amiel; G Plewe; R S Sherwin; H A Pearson; W V Tamborlane
Journal:  N Engl J Med       Date:  1988-03-31       Impact factor: 91.245

Review 9.  SQUID biosusceptometry in the measurement of hepatic iron.

Authors:  Sujit Sheth
Journal:  Pediatr Radiol       Date:  2003-03-21

10.  Non-invasive liver iron quantification by SQUID-biosusceptometry and serum ferritin iron as new diagnostic parameters in hereditary hemochromatosis.

Authors:  Peter Nielsen; Rainer Engelhardt; Jochen Düllmann; Roland Fischer
Journal:  Blood Cells Mol Dis       Date:  2002 Nov-Dec       Impact factor: 3.039

View more
  9 in total

1.  An assessment of iron overload in children treated for cancer and nonmalignant hematologic disorders.

Authors:  Jelena Rascon; Lina Rageliene; Sigita Stankeviciene; Darius Palionis; Algirdas Edvardas Tamosiunas; Nomeda Valeviciene; Tadas Zvirblis
Journal:  Eur J Pediatr       Date:  2014-09       Impact factor: 3.183

2.  Automated vessel exclusion technique for quantitative assessment of hepatic iron overload by R2*-MRI.

Authors:  Aaryani Tipirneni-Sajja; Ruitian Song; M Beth McCarville; Ralf B Loeffler; Jane S Hankins; Claudia M Hillenbrand
Journal:  J Magn Reson Imaging       Date:  2017-10-30       Impact factor: 4.813

3.  Radial Ultrashort TE Imaging Removes the Need for Breath-Holding in Hepatic Iron Overload Quantification by R2* MRI.

Authors:  Aaryani Tipirneni-Sajja; Axel J Krafft; M Beth McCarville; Ralf B Loeffler; Ruitian Song; Jane S Hankins; Claudia M Hillenbrand
Journal:  AJR Am J Roentgenol       Date:  2017-05-15       Impact factor: 3.959

4.  Assessment of MR-based R2* and quantitative susceptibility mapping for the quantification of liver iron concentration in a mouse model at 7T.

Authors:  Gregory Simchick; Zhi Liu; Tamas Nagy; May Xiong; Qun Zhao
Journal:  Magn Reson Med       Date:  2018-03-25       Impact factor: 4.668

5.  Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study.

Authors:  A Sirvent; P Auquier; C Oudin; Y Bertrand; S Bohrer; P Chastagner; M Poirée; J Kanold; S Thouvenin; Y Perel; D Plantaz; M-D Tabone; K Yakouben; V Gandemer; P Lutz; N Sirvent; C Vercasson; J Berbis; H Chambost; G Leverger; A Baruchel; G Michel
Journal:  Bone Marrow Transplant       Date:  2016-09-05       Impact factor: 5.483

6.  Hepatic late adverse effects after antineoplastic treatment for childhood cancer.

Authors:  Renée L Mulder; Dorine Bresters; Malon Van den Hof; Bart Gp Koot; Sharon M Castellino; Yoon Kong K Loke; Piet N Post; Aleida Postma; László P Szőnyi; Gill A Levitt; Edit Bardi; Roderick Skinner; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2019-04-15

7.  Ultrashort echo time imaging for quantification of hepatic iron overload: Comparison of acquisition and fitting methods via simulations, phantoms, and in vivo data.

Authors:  Aaryani Tipirneni-Sajja; Ralf B Loeffler; Axel J Krafft; Andrea N Sajewski; Robert J Ogg; Jane S Hankins; Claudia M Hillenbrand
Journal:  J Magn Reson Imaging       Date:  2018-10-25       Impact factor: 4.813

8.  Serum Alanine Aminotransferase Elevations in Survivors of Childhood Cancer: A Report From the St. Jude Lifetime Cohort Study.

Authors:  Daniel M Green; Mingjuan Wang; Matthew J Krasin; DeoKumar Srivastava; Mary V Relling; Carrie R Howell; Kirsten K Ness; Sue C Kaste; William Greene; Dennis W Jay; Israel Fernandez-Pineda; Ching-Hon Pui; Sima Jeha; Michael W Bishop; Wayne L Furman; Leslie L Robison; Melissa M Hudson
Journal:  Hepatology       Date:  2018-12-25       Impact factor: 17.425

9.  Blood product administration during high risk neuroblastoma therapy.

Authors:  Allison Silverstein; Kiranmye Reddy; Valeria Smith; Jennifer H Foster; Heidi V Russell; Sarah B Whittle
Journal:  Pediatr Hematol Oncol       Date:  2019-12-12       Impact factor: 1.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.